Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia.

IF 4.5 2区医学 Q1 CLINICAL NEUROLOGY

International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI:10.1093/ijnp/pyaf032

Michael Davidson, Nadine Noel, Florent Schmitt, Remy Luthringer

引用次数: 0

Abstract

Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.

查看原文本刊更多论文

鲁哌酮单药治疗精神分裂症阴性症状。

罗鲁哌酮是一种正在开发的药物，针对精神分裂症的原发性阴性症状，结合sigma- 2,5 - ht2a和alpha1a受体。在两项临床试验中，罗鲁哌酮作为单一疗法用于患有轻度至中度阴性症状并停用抗精神病药物的患者，改善了阴性症状。停用抗精神病药物前症状稳定3 - 6个月的患者，在6 - 9个月的试验期间精神病症状恶化的发生率极低。焦点：精神分裂症患者亚组原发性阴性症状的治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Neuropsychopharmacology 医学-精神病学

CiteScore

8.40

自引率

2.10%

发文量

230

审稿时长

4-8 weeks

期刊介绍： The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.